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Pancreatic cancer is characterized by an extensive desmoplastic stroma, the functional relevance of which is poorly
understood. Activated fibroblasts are a prevalent component of the stroma, and traditionally, these cells have been
considered as a homogenous population derived from pancreatic stellate cells. In this study, we highlight a previously
unappreciated heterogeneity of the fibroblast populationwithin the stroma. In particular, a subset of stromal fibroblasts has
characteristics of mesenchymal stem cells (MSCs). MSCs are present in the normal pancreas as well as in the
carcinomatous pancreas (CA-MSCs). Here, we determine that CA-MSCs have increased tumor-promoting function
comparedwithMSCs in normal pancreas. This ability to promote tumor growth is associatedwith CA-MSCs’ unique ability
to promote alternative macrophage polarization. Thus, our study identifies a previously uncharacterized cell population
within the stroma and sheds light on tumor-promoting interactions between different components of the stroma.
Significance
Targeting thestroma isemergingasanewparadigm inpancreatic cancer;however, efforts to thateffect arehamperedbyour limited
understandingofthenatureandfunctionofstromalcomponents.Here,weuncoverpreviouslyunappreciatedheterogeneitywithinthe
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Pancreatic cancer is among the deadliest of human malignancies. A
prominent feature of pancreatic cancer is an extensive reactive stroma,
which can comprise up to 90% of the overall tumor volume, the
highest fraction of all solid, epithelial tumors (for review, see [1]). The
accumulation of a desmoplastic stroma occurs from the onset of
pancreatic carcinogenesis and is evident in the precursor lesions of
pancreatic cancer known as pancreatic intraepithelial neoplasia or
PanINs [2]. The cellular components of the stroma include
fibroblasts, myofibroblasts, endothelial cells, and infiltrating immune
cells [3,4]. Fibroblasts are an abundant and poorly characterized
component of the stroma, thought to derive from pancreatic stellate
cells. Fibroblasts within the stroma have been thought of as protumor
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that stromal fibroblasts might act to restrain tumor growth [6,7].
This controversy might in part reflect our limited understanding of
cellular components of the stroma and their individual contribution
to tumorigenesis.
The healthy pancreas includes different fibroblast populations. A
population of mesenchymal stem cells (P-MSCs) was identified in the
normal human and mouse pancreas [8,9]; however, whether MSCs
are present in pancreatic carcinoma and what their function might be
during carcinogenesis remained unclear. MSCs were identified as a
tumor-promoting stromal component in several epithelial cancers
[10–12]. Interestingly, the manner in which MSCs promote
tumorigenesis is distinct in each tumor context. In breast cancer,
bone marrow–derived MSCs promote the metastasis of tumor cells
through a CCL5-mediated effect [11]. In ovarian cancer, MSCs
isolated from the tumor stroma secrete bone morphogenic proteins
(BMPs) that increase the cancer stem cell population [12]. More
recently, stroma-derived MSCs from lymphomas have been shown to
secrete monocyte/macrophage chemoattractants, which in turn
promote tumor growth [13].
The identification and characterization of MSCs in pancreatic
tumor growth are the focus of the current study. We use a
genetically engineered mouse model of pancreatic cancer, the KC
mouse (Ptf1a-Cre;LSL-KrasG12D) [14], that expresses an oncogenic
form of Kras, thus recapitulating the most common genetic
alteration in human PanINs and pancreatic cancer [15,16]. KC
mice develop PanINs in a stepwise manner that recapitulates human
carcinogenesis [14]. Our results show that MSC populations are
present in both the normal murine pancreas (P-MSCs) and
neoplastic mouse pancreas (carcinogenesis-associated MSCs,
CA-MSCs). By performing functional comparisons of these two
populations, we determined that CA-MSCs have an increased
tumor-promoting potential, which is mediated, at least in part, by
their unique ability to induce macrophage polarization to a
protumor, alternatively activated status.
Results
MSCs in the Normal and in the Neoplastic Pancreas
MSCs are defined by their ability to differentiate into osteoblasts,
chondrocytes, and adipocytes when exposed to appropriate differen-
tiation media in vitro. To test whether we could identify an MSC
population in the normal and neoplastic murine pancreas, we isolated
pancreata from wild-type and littermate KC mice 3 weeks following
caerulein-induced acute pancreatitis. Wild-type pancreata have
completed the tissue repair process by this time, whereas in KC
pancreata, extensive PanINs surrounded by desmoplastic stroma are
evident (Figure 1A). Isolated bulk fibroblast populations from the
pancreata were exposed to osteoblast, adipocyte, and chondrocyte
differentiation media. Trilineage differentiation was observed both in
the wild-type and in the KC-derived pancreata, indicating that an
MSC population might exist in both settings (Figure 1B). Thus, our
data confirmed the presence of an MSC population in the normal
pancreas, as previously described [8,9,17], and identified a similar
population in the neoplastic pancreas. MSCs have been isolated based
on the expression of a panel of surface markers: CD45−;CD44+;-
CD49a+:CD73+;CD90+ [18]. To determine whether these markers
were sufficient to isolate the MSC population in the pancreas, we
isolated single-cell suspensions from wild-type and KC pancreata 3weeks after the induction of pancreatitis (n = 3 mice/genotype) and
used fluorescent-activated cell sorting to isolate and quantify cells
expressing MSC markers. Although CD45−;CD44+;CD49a+:
CD73+;CD90+cells were present in both sample sets, their number
was significantly higher in KC pancreata compared with the normal
mouse pancreas (Figure 1A). To determine whether the surface
markers did indeed identify the MSC population, we cultured
CD44+;CD49a+:CD73+;CD90+ cells (putative MSCs, 4+) as well as
cells negative for all markers (4neg) and performed in vitro
differentiation assays with protocols promoting osteoblast and
adipocyte lineages. In differentiation media, CD45−;CD44+;
CD49a+:CD73+;CD90+ cells from both the normal and neoplastic
pancreas could differentiate into osteoblasts as determined by Alizarin
Red staining of calcium deposits, and expression of the osteoblast
marker alkaline phosphatase by quantitative reverse transcriptase
polymerase chain reaction (qRT-PCR) analysis (Figure 1, C and D,
top row). Likewise, CD45−;CD44+;CD49a+:CD73+;CD90+ cells
could differentiate into adipocytes as determined by Oil Red O
staining of lipid droplets and expression of adipocyte marker fatty acid
binding protein 4 (Fabp4) (Figure 1, C and D, bottom row). In
contrast, 4neg cells did not differentiate into any of the lineages
(Figure 1, C and D), indicating that the combination of CD44+,
CD49a+, CD73+ and CD90+ surface markers identifies a subset of
multipotent cells.
Distinct Cytokine Expression Profile in CA-MSCs
Because MSCs were present both in the normal and in the
neoplastic pancreas, we set out to compare their functional
characteristics. Hereby, normal pancreas–derived MSCs are referred
to as P-MSCs, wherease MSCs derived from the neoplastic pancreas
are referred to as CA-MSCs (carcinoma-associated MSCs). In ovarian
cancer, CA-MSCs are distinct from bone marrow and adipose-derived
MSCs by the expression of BMP2 and BMP4 [12], and those factors
confer a higher tumor-promoting ability to CA-MSCs. Thus, we
measured the relative expression of BMP2 and BMP4 by qRT-PCR
in isolated P-MSCs and CA-MSCs. We detected no difference in
BMP2 expression, whereas BMP4 expression was decreased in
CA-MSCs compared with P-MSCs (Figure S1A).
We have previously shown that pancreatic fibroblasts secrete a
number of cytokines that regulate the infiltration of immune cells
during pancreatic damage and repair and during carcinogenesis [19].
Thus, we measured expression of those cytokines by qRT-PCR in
freshly sorted P-MSCs and CA-MSCs. Interestingly, we observed a
significant increase in several cytokines known to promote
tumorigenesis, including IL-6, IL-10, and TGFβ [20–24]
(Figure 1E), in CA-MSCs compared with P-MSCs. Then, we
measured the expression of the same subset of cytokines in cultured
CA-MSCs and P-MSCs, respectively, and found a similar profile,
with significantly elevated cytokines in CA-MSCs (Figure S1B).
SimilarlyM-CSF and GM-CSF, cytokines known to regulate immune
cell recruitment and function, were significantly elevated in
CA-MSCs compared with P-MSCs. Finally, we compared paired
bone marrow and pancreatic MSCs extracted from a control mouse
(P-BMMSCs and P-MSCs) or a PanIN-bearing KC mouse (CA-BM
MSCs and CA-MSCs). P-MSCs expressed higher levels of IL6,
Cox-2, and IL10 than their bone marrow counterparts. CA-MSCs
expressed higher levels of IL6, Cox-2, TGFβ, and IL-10 than both
P-MSCs and CA-BM MSCs (Figure S1C). These data indicate that
MSCs extracted from the neoplastic pancreas have unique
Figure 1.Multipotentstromalcells (MSCs)arepresent inthepancreas. (A)MSCsare increasedintheneoplasticpancreascomparedwiththenormalpancreas
asquantifiedbyflowcytometry.Scalebarforrepresentativehematoxylinandeosin(H&E) images,50μm.(B)Stromalcells isolatedfromtheneoplasticpancreas
can differentiate into osteoblasts (top row), chondrocytes (middle row), and adipocytes (bottom row). (C) P-MSCs can differentiate into bone (top row) and fat
(bottom row). (D) CA-MSCs can differentiate into bone (top row) and fat (bottom row). (E) qRT-PCR onMSCs freshly sorted from the pancreas.
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Figure 2. CA-MSCs promote tumor growth. (A) Experimental design. (B) Gross tumor morphology and final tumor weights. Scale bar
represents 0.5 cm. (C) Histopathological analysis of tumors following coinjection. H&E staining; scale bar represents 50 μm. (Inset) F4/80
staining; scale bar represents 50 μm. (D) Immunohistochemistry for Ck19; scale bar represents 20 μm. (E) Immunohistochemistry for
Ki67 (green) and Ck19 (red); scale bar represents 20 μm. (F) Quantitation of Ki67 staining. (G) Flow cytometry analysis of macrophages. (H)
qRT-PCR analysis for Mcp-1 and (I) M-csf.
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igure 3. Myeloid cells are vital for CA-MSC–mediated tumor growth. (A) Schematic for Cd11b-DTR mouse. (B) Experimental design.
, Left) Final tumor weights. Data are presented as mean ± SEM. (Right) Percentage decrease in tumor weights. (D) Histopathological
nalysis of tumors following coinjection. H&E staining; scale bar represents 50 μm. (Inset) F4/80 staining; scale bar represents 50 μm.
) Immunohistochemistry for Ki67; scale bar represents 20 μm.
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normal organ nor by MSCs extracted by different organs (in this case,
the bonemarrow) of amouse bearing neoplastic changes in the pancreas.
MSCs Pancreatic Tumor Growth
To determine the functional effect of MSCs on tumor growth,
we performed subcutaneous coinjections of tumor cells and MSCs
into immunocompetent mice using a littermate syngeneic approach.
We used tumor cells isolated from the iKras*p53* model [25] of
pancreatic cancer (iKras*p53*#3 cells [26]) or tumor cells derived
from the KPC mouse model [27] of pancreatic cancer (13442 cells).
Tumor cells were injected at a 1:1 ratio with either P-MSCs or
CA-MSCs (see schematic in Figures 2A and S2A). Coinjection of
P-MSCs with iKras*p53*#3 or 13442 tumor cells promoted tumor
growth, but coinjection of CA-MSCs promoted even larger tumor
growth (Figures 2B and S2B). The histology of all three cohorts was
similar, with epithelial structures surrounded by abundant stroma
(Figures 2C and S2C). Staining for Ck19 to mark tumor cells revealed
increased number of tumor cells in coinjections with CA-MSCs
(Figures 2D and S2D). Consistently, we detected increased
intratumor proliferation—as indicated by Ki67 staining—in coinjec-
tions with CA-MSCs. Immunofluorescence analysis revealed a
notable increase in proliferating tumor Ck19+ cells, indicating an
increase in proliferating tumor cells (Figures 2, E and F, and S2, D
and E). To determine whether MSCs were still able to promote
tumor growth when injected at a lower ratio, we performed a parallel
set of experiments by injecting tumor cells (13442) andMSCs at a 2:1
ratio. We found that, at this lower ratio, P-MSCs were unable to
promote tumor growth, whereas in contrast, CA-MSCs still
promoted tumor growth, further validating the concept that
CA-MSCs have increased tumor-promoting ability (Figure S2K).
Because our data indicated that CA-MSCs have different
functional characteristics than P-MSC, we expanded our character-
ization to include bone marrow–derived MSCs (BM-MSCs). In the
absence of rigorous lineage tracing studies, it is not known whether
CA-MSCs derived from P-MSCs or, at least in part, from infiltrating
BM-MSCs, as observed in other disease contexts [28,29]. This is a
question that warrants further studies that are beyond the scope of the
current manuscript. BM-MSCs from a control mouse promoted
tumor growth similarly to P-MSCs. However, CA-MSCs were able to
promote significantly more tumor growth than their bone marrow–
derived counterparts (Figure S2, I and J). Thus, CA-MSCs have a
unique tumor promoting ability; we then set out to understand the
mechanistic basis for this finding.
Given our previous observation that CA-MSCs secreted a number of
cytokines that are known to regulate macrophages, we sought to
determine the effect of MSC coinjection on macrophage infiltration
within the tumor. Thus, we stained tissues for F4/80, a mature
macrophage marker. We detected a significant increase in macrophages
in the tumors derived from coinjection of tumor cells and CA-MSCs
(Figures 2C and S2C, insets) compared with tumor cells alone or
coinjected with P-MSCs. To quantify macrophage numbers in the
subcutaneous tumors, we performed flow cytometry for macrophages
defined as CD11b+;CD64+;F4/80+ cells. We found that tumors
derived from the CA-MSC coinjection consistently had the highest
population of macrophages compared with the other experimental
cohorts, thus corroborating the histology (Figures 2G and S2F).
Monocyte migration to the tumor stroma and subsequent
differentiation into macrophages are processes orchestrated by anarray of signaling molecules. To assess potential differences in these
cytokine levels between tumor cohorts, we collected RNA from
subcutaneous tumor tissue for qRT-PCR analysis. We found that
expression of Mcp-1, a potent monocyte chemoattractant, did not
differ between tumors coinjected with P-MSCs or with CA-MSCs
but, at least for tumors derived from the 13442 line, was higher in the
MSC-coinjected tumors than in the control group (Figures 2H and
S2G). Interestingly, we detected an increase in M-CSF in coinjections
with CA-MSCs (Figures 2I and S2H), a cytokine that supports the
differentiation of monocytes into macrophages.
Requirement for Monocytes/Macrophages in MSC-driven
tumor growth
Macrophages have been shown to promote pancreatic growth
[30]. Thus, based on the observation that CA-MSCs promoted the
highest infiltration of macrophages, we next tested whether this
population’s elevated tumor-promoting potential required macro-
phages. To achieve this, we coinjected tumor cells and MSCs into
immunocompetentmice with concomitant depletion ofmonocytes and
macrophages. Cd11b-DTR mice express the human diphtheria toxin
receptor under the Cd11b promoter (Figure 3A). Administration of
diphtheria toxin (DT) to Cd11b-DTRmice depletes all CD11b+ cells,
including monocytes and macrophages [31]. We performed a series of
coinjection experiments with iKras*p53*#3 cells alone or in combina-
tion with P-MSCs or CA-MSCs. In a subset of each cohort, mice were
injected with DT (Figure 3B). We confirmed DT-mediated depletion
by staining tumor tissues for F4/80; in all cohorts, DT administration
significantly attenuated macrophage infiltration (Figure 3D, inset). We
found that tumor size was reduced by depleting CD11b+ cells in all
experimental cohorts, underscoring the importance of myeloid cells in
tumor growth. However, coinjections of iKras*p53*#3 cells with
CA-MSCs were significantly more susceptible to myeloid cell ablation
than any other experimental cohort, both in terms of tumor mass
changes (Figure 3C) and when considering the ratio of epithelial cells
within the tumor (Figure 3D). The susceptibility of CA-MSCs to
myeloid cell depletion was consistently observed using distinct MSC
lines (Figure S3D). Whereas the tumor histology remained similar
(Figure 3D), immunostaining for Ck19 revealed a reduction in the ratio
of epithelial cells within the tumors (Figure S3A). Moreover, although
tumors derived from coinjections with CA-MSCs are more proliferative
than the other cohorts, this increase in proliferation was abrogated upon
myeloid cell depletion (Figure 3E).
To determine whether the dependence on myeloid cells for tumor
promotion was a unique property of CA-MSCs or rather a common
feature of fibroblasts derived from the neoplastic pancreas, we
performed parallel coinjection experiments with non-MSCs (CD45−;
CD44−;CD49a−:CD73−;CD90−) sorted from the neoplastic stroma
(CA-non-MSCs) (Figure S3B). Although these cells also promoted
tumor growth, the extent of tumor mass reduction upon CD11b+
cell depletion was less than in coinjections with MSCs (Figure S3C).
Thus, CA-MSCs have a unique dependence on myeloid cells, which
led us to investigate the interaction between these cell types.
MSCs Promote Macrophage Differentiation and Polarization
to an Alternatively Activated Subtype
Pancreatic cancer fibroblasts, including the FAP+ subset, are
known to modulate the immune response, thus affecting tumor
growth [32,33]. To directly interrogate whether MSCs directly
regulate macrophage polarization, we investigated their interactions
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the differentiation of monocytes into macrophages. For this purpose,
we isolated and cultured mouse bone marrow precursors. After 1
week of culture in regular medium, about 25% of the cell population
differentiates to macrophages, defined as CD11b+;CD64+;F4/80+
cells by flow cytometry. As expected based on previous studies [34],
exposure to M-CSF–supplemented media led to differentiation of a
uniform population of CD11b+;CD64+;F4/80+ macrophages
(Figure 4A). We tested the effect of supplementing the culture
medium with conditioned media from either P-MSCs or CA-MSCs,
as well as P-non-MSCs and CA-non-MSCs (pancreatic fibroblasts or
neoplastic fibroblasts). Both P-MSCs and CA-MSCs promoted
macrophage differentiation in more than 50% of the bone marrow
precursors, with no significant difference between the two popula-
tions. In contrast, only non-MSC fibroblasts from the neoplastic
pancreas could also promote macrophage differentiation, although to
a lesser extent than their MSC counterparts (Figure 4A).
We next assessed whether P-MSCs or CA-MSCs regulated
macrophage polarization. First, we performed qRT-PCR to evaluate
gene expression indicating either classically or alternatively activated
macrophage polarization RNA collected from our subcutaneous
coinjection experiments (Figure S4, A and B). We found that tumors
derived from coinjection with both P-MSCs and CA-MSCs had
decreased expression of iNos, a classically activated marker, compared
with tumor cells injected alone. However, only coinjections with
CA-MSCs tumor cells showed increased expression of Arg1 and
CD206, both markers of alternatively activated macrophages.
Likewise, the expression of IL10, a cytokine known to induce
alternative macrophage differentiation, was significantly increased in
coinjections with CA-MSCs (Figure S4, A and B). Importantly, these
changes were observed with both iKras*p53* and KPC tumor cells.
To test whether MSCs directly regulated macrophage polarization
to an alternatively activated phenotype, we treated three indepen-
dently derived cultures of bone marrow–derived macrophages
(BMDMs) with conditioned media from either P-MSCs or
CA-MSCs for 12 hours (Figure 4B). We found that both P-MSC–
and CA-MSC–conditioned media decreased iNOS expression in
BMDMs compared with control medium, indicating suppression of
the classically activated subtype. However, only CA-MSC–conditioned
medium promoted alternatively activated macrophage polarization, as
determined by Arg1 expression (Figure 4C). We then repeated this set
of experiments using the mouse macrophage cell line RAW264.7 that
can be polarized in culture. Conditionedmedium from P-MSCs had no
effect on the expression of iNos or Arg1 in macrophages. In contrast,
whereas conditioned medium from CA-MSCs stimulated a four-fold
increase in iNos expression, Arg1 expression was increased more than
one-hundred–fold.We also tested the effect of conditioned media from
bone marrow MSCs, which have been reported to induce Arg1
expression in macrophages, leading to an alternatively activated
phenotype [35,36]. We found that whereas CA BM-MSCs couldFigure 4. CA-MSC–derived IL6 and IL10 promote alternatively activat
differentiated macrophages. Each data point represents bone marrow
on BMDMs for iNOS (left) and Arg1 (right). Each data point represents
for iNOS (left) and Arg1 (right). (E) Western blot analysis of RAW264
qRT-PCR on RAW264.7 macrophages treated with conditioned med
CA-MSC–stimulated cells. (G) Working model of CA-MSC–mediatedpromoteArg1 expression, this effect was significantly less than CA-MSCs
(Figure 4D). Likewise, CA-MSCs could stimulate significantly greater
Arg1 expression than CAFs (non–CA-MSCs) (Figure S4C). Taken
together, our data indicate that the ability to promote alternatively
activated macrophage polarization is restricted to CA-MSCs.
As CA-MSCs expressed significantly higher IL-6 and IL-10
compared with P-MSCs and these cytokines are known to regulate
macrophage polarization, we tested whether production of these
cytokines explained the unique ability of CA-MSCs to promote
macrophage alternative activation. Thus, we treated RAW264.7
macrophages with CA-MSC conditioned media with and without an
IL-6–neutralizing antibody or an IL-10–neutralizing antibody and
assessed Arg1 expression. Consistent with IL-6 stimulation, CA-MSC
conditioned medium increased pSTAT3(Y705) levels in RAW264.7
macrophages compared with control medium, and this increase was
abrogated by the anti-IL6 antibody but not by the anti-IL10 antibody
(Figure 4E). Treatment with CA-MSC conditioned medium induced
Arg1 expression in RAW264.7macrophages; this induction was partially
abrogated by anti-IL6 and, to a lesser extent, by anti-IL10 treatment
(Figure 4F). Concomitant treatment with anti-IL6 and anti-IL10
antibodies completely blocked the induction of Arg1 expression,
indicating that these two cytokines might act along parallel, nonover-
lapping paths. We then investigated the effect of CA-MSC conditioned
medium on the expression of classically activated differentiationmarkers.
We observed no change in iNOS expression but a reduction of IL12p35
upon treatment with conditioned medium (Figure S4, D and E). This
decrease was reversed with higher concentrations of either IL6 or IL10
inhibition. Taken together, our results show that both P-MSCs and
CA-MSCs can induce macrophage differentiation for a precursor
population, but only CA-MSCs specifically direct polarization to a
tumor-promoting, alternatively activated subtype.
Discussion
Fibroblasts exist in every tissue and organ in the body and are a
prevalent population within the pancreatic cancer stroma. Our
understanding of their functional specificity, however, remains
limited. Here, we have identified a subpopulation of fibroblasts
present both within the normal pancreas and in the neoplastic
pancreas, with MSC characteristics, namely, the ability to differen-
tiate into chondrocytes, adipocytes, and osteoblasts. We determined
that MSCs from the neoplastic pancreas (CA-MSCs) have a unique
ability to promote tumor growth that depends on their ability to
promote infiltration of monocytes/macrophages and their
differentiation to an alternatively activated, tumor-promoting,
phenotype (Figure 4G). Our study highlights the functional
heterogeneity of stromal fibroblast populations and the different
functional properties of fibroblasts derived from the normal or
neoplastic organ. Furthermore, our study identifies novel interac-
tions between the fibroblast population and the immune component
of pancreatic cancer.ed macrophage polarization. (A) Flow cytometry analysis of in vitro
precursors from one mouse. (B) Experimental design. (C) qRT-PCR
BMDMs from onemouse. (D) qRT-PCR on Raw264.7 macrophages
.7 macrophages treated with conditioned media and inhibitors. (F)
ia and inhibitors for Arg1. # indicates significant differences from
promotion of tumor growth.
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Detailed reagent information and experimental procedures are
provided in Supplemental Experimental Procedures.
Statistical Analysis
Student's t tests were used to compare experimental cohorts, and
significance was established for P values b .05. Significance values
indicated by asterisks or pound signs are as follows: *P b .05, **P b .01,
***P b .0005, and ****P b .0001.
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